Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Uranium Energy Corp — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.96 (market cap $8.48B), while Uranium Energy Corp trades at $7.58 (market cap $4.08B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 2.1× Uranium Energy Corp's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Uranium Energy Corp for 38 Days on average.
| HNGE | UEC | |
|---|---|---|
Market Cap | $8.48B | $4.08B |
Volume | 879,799 | 14,920,249 |
Sector | Health | Energy |
52-Week High | $105.14 | $20.14 |
52-Week Low | $31.17 | $7.70 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $8.10B | $3.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Uranium Energy (UEC) trades at $8.25, down 6.57% today, amid bearish technical signals despite strong analyst support. The company shows operational improvements with multi-mine expansion but faces fundamental challenges with negative net income margins (-368.62%) and declining revenue from $67M in 2025 to $37M in 2026. Recent Q4 2026 earnings beat revenue estimates but missed on EPS, while technical indicators show 18 sell signals versus 3 buy signals.
The stock presents a high-risk opportunity with Wall Street optimism (87.5% buy ratings, $16.06 consensus target) contrasting with weak financials. Key risks include unsustainable production growth, dependence on inventory sales, and cash flow challenges. Upside depends on successful execution of uranium production ramp-up and favorable government demand trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
